



Delphi Panel Members

The Task Force is grateful to all those who participated in the Delphi Panel:

Fernando Antoñanzas, Universidad de la Rioja
Steve Beard, RTI International
Marc Berger, Pfizer Inc.
Philip Clarke, University of Oxford
John Cook, Merck & Co. Inc.
Doug Coyle, University of Ottawa
Dawn Craig, University of York
Stephanie Earnshaw, RTI International
Alastair Fisher, University of Oxford
Kevin Frick, John Hopkins Bloomberg School of Public Health
Alastair Gray, University of Oxford
Alan Haycox, University of Liverpool
Jonathan Karnon, University of Adelaide
Karen Lee, Canadian Agency for Drugs and Technologies in Health
Eric Lun, Government of British Columbia
Marjukka Mäkelä, International Journal of Technology Assessment in Health Care
Silas Martin, Janssen Scientific Affairs, LLC
Andrea Manca, University of York
Karl Matuszewski, First DataBank
Richard Milne, Health Outcomes Associates Ltd.; University of Auckland
Cindy Mulrow, Annals of Internal Medicine
Ken Patterson, New Drugs Committee of the Scottish Medicines Consortium
Andrés Pichon-Riviere, Instituto de Efectividad Clínica y Sanitaria (IECS)
Joseph Pliskin, Harvard School of Public Health
Jason Roberts, International Society of Managing and Technical Editors
Joan Rovira, BMC Cost Effectiveness and Resource Allocation
Chris Schmid, Institute for Clinical Research and Health Policy Studies at Tufts Medical Center
Rico Schoeler, Pharmaceutical Management Agency of New Zealand (PHARMAC)
Paul Scuffham, Griffith University, Australia
Hans Severens, Institute of Medical Technology Assessment at Erasmus University Rotterdam
Joanna Siegel, Agency for Healthcare Research and Quality (AHRQ)
Mendel Singer, Case Western Reserve University
Baudouin Standaert, GSK
Kenneth Stein, Peninsula College of Medicine and Dentistry, University of Exeter
Tom Trikalinos, Brown University
Milton Weinstein, Harvard School of Public Health
Richard Willke, Pfizer Inc.